ICPT Intercept Pharmaceuticals Inc

Price (delayed)

$15.72

Market cap

$467.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$1.12B

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded ...

Highlights
The net income has surged by 69% year-on-year and by 25% since the previous quarter
The EPS has soared by 67% year-on-year and by 23% since the previous quarter
The quick ratio is up by 4.9% since the previous quarter but it has declined by 4.8% year-on-year
The equity has plunged by 102% from the previous quarter and by 86% YoY
ICPT's debt is up by 33% since the previous quarter and by 26% year-on-year

Key stats

What are the main financial stats of ICPT
Market
Shares outstanding
29.71M
Market cap
$467.02M
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.04
Earnings
Revenue
$370.39M
EBIT
-$19.62M
EBITDA
-$11.56M
Free cash flow
-$7.14M
Per share
EPS
-$2.2
Free cash flow per share
-$0.24
Book value per share
-$12.52
Revenue per share
$12.47
TBVPS
$16.95
Balance sheet
Total assets
$503.36M
Total liabilities
$875.12M
Debt
$716.89M
Equity
-$371.76M
Working capital
$326.32M
Liquidity
Debt to equity
-1.93
Current ratio
3.16
Quick ratio
3
Net debt/EBITDA
-56.89
Margins
EBITDA margin
-3.1%
Gross margin
99.2%
Net margin
-18.4%
Operating margin
-9.9%
Efficiency
Return on assets
-13.2%
Return on equity
N/A
Return on invested capital
-2.3%
Return on capital employed
-5.6%
Return on sales
-5.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICPT stock price

How has the Intercept Pharmaceuticals stock price performed over time
Intraday
2.81%
1 week
13.83%
1 month
7.97%
1 year
-17.18%
YTD
-3.5%
QTD
13.83%

Financial performance

How have Intercept Pharmaceuticals's revenue and profit performed over time
Revenue
$370.39M
Gross profit
$367.34M
Operating income
-$36.6M
Net income
-$68.29M
Gross margin
99.2%
Net margin
-18.4%
Intercept Pharmaceuticals's operating margin has surged by 82% YoY and by 35% QoQ
Intercept Pharmaceuticals's operating income has surged by 79% YoY and by 34% QoQ
ICPT's net margin has soared by 73% year-on-year and by 27% since the previous quarter
The net income has surged by 69% year-on-year and by 25% since the previous quarter

Growth

What is Intercept Pharmaceuticals's growth rate over time

Valuation

What is Intercept Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.04
The EPS has soared by 67% year-on-year and by 23% since the previous quarter
The equity has plunged by 102% from the previous quarter and by 86% YoY
ICPT's price to sales (P/S) is 86% lower than its 5-year quarterly average of 9.0 and 18% lower than its last 4 quarters average of 1.5
ICPT's revenue is up by 15% year-on-year

Efficiency

How efficient is Intercept Pharmaceuticals business performance
The ROS has soared by 90% year-on-year and by 48% since the previous quarter
Intercept Pharmaceuticals's return on invested capital has surged by 88% YoY and by 49% QoQ
Intercept Pharmaceuticals's return on assets has surged by 65% YoY and by 25% QoQ

Dividends

What is ICPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICPT.

Financial health

How did Intercept Pharmaceuticals financials performed over time
The total assets is 42% smaller than the total liabilities
Intercept Pharmaceuticals's total liabilities has increased by 23% QoQ and by 22% YoY
Intercept Pharmaceuticals's current ratio has decreased by 5% YoY but it has increased by 5% from the previous quarter
The equity has plunged by 102% from the previous quarter and by 86% YoY
Intercept Pharmaceuticals's debt to equity has increased by 34% QoQ and by 32% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.